DAK Gesundheit Tender

Contract notice: conclusion of a non-exclusive discount agreement according to § 130a para. 8 sgb v on the active ingredient follitropin alfa, atc g03ga05, for the period 01.02.2022 - 31.01.2024 Section 130a, paragraph 8 of the german code of civil law (sgb) v enables health insurers and pharmaceutical companies to conclude framework discount agreements for the medicinal products that are to be paid for by statutory health insurances. with regard to the relevant legal regulations for the award of public contracts, there is a regular process of active substance-related, formal award procedures in accordance with the regulations of the 4th part of the gwb by the dak-gesundheit. for medicinal products to be specified by the bidder in annex 2 to the contract for the above. active ingredient follitropin alfa, atc g03ga05, dak-gesundheit intends to conclude drug discount agreements with as many interested pharmaceutical companies as possible until new drug discount agreements come into effect. a discount contract i.R.D. approval model for the above active ingredient first comes into effect on 02/01/2022 and ends on 01/31/2024. regardless of this, it ends automatically when the exclusive contract comes into force.Dak-gesundheit assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and therefore the non-discriminatory accessibility of all pharmaceutical companies. regardless of this, it ends automatically with the entry into force of the exclusive contract for follitropin alfa, atc g03ga05, as a result of a formal award procedure in accordance with the regulations of the 4th part of the gwb with one or more contractual partners. in order to do justice to the diversity of potential contractual partners within the framework of the approval model, every pharmaceutical company is able to conclude a framework agreement at any time and under the same conditions during the term of the contract. the contract documents required for this are available on the online portal www.Dtvp.De/center under i.3. the following documents must be sent in full and in good time (available for download under the link mentioned under i.3.) to the following department at dak health: 1. offer letter2. recognition of the contractual stipulations of dak health, in particular the given discounts, by submitting the contract with the name or company stamp by the interested party at the designated point. the completed annexes 1 and 2 to the contract. the interested party has to enter the medicinal products for the above-mentioned active ingredient, which are to become the subject matter of the contract. the documents are to be submitted by e-mail to: openhouse@dak.Dedak-gesundheitfachbereich arzneimittel (0038 00) nagelsweg 27-3120097 hamburg annex 2 is expressly as an excel file send to the e-mail address openhouse@dak.De. contracts within the framework of this model and the above-mentioned active ingredient will be concluded f